INS and polycystic ovary syndrome: The development of GLP-1 receptor agonists and their proven benefits in improving insulin sensitivity, body weight, and BMI suggest a promising therapy for patients with PCOS due to the overlapping pathophysiology between the condition and the medications’ current approved uses.